For decades, the six-week antibiotic course for infective endocarditis has been more tradition than evidence — a consensus-driven standard with real costs in side effects, hospital stays, and resistance risk. A large international randomized trial now puts that assumption to the test, with implications not just for endocarditis management but for how medicine rethinks prolonged antibiotic dogma more broadly.
The NEJM-published trial enrolled 508 adults with left-sided infective endocarditis caused by three of the most clinically significant pathogens: Staphylococcus aureus, Enterococcus faecalis, or streptococcal species. Crucially, all participants had already completed at least two to four weeks of intravenous antibiotics and met predefined clinical stabilization criteria before randomization. The tailored group then discontinued treatment entirely, while the standard group continued to a total of four to six weeks. The primary efficacy measure — days alive and antibiotic-free within six months — favored the shorter approach, while the composite safety endpoint (all-cause mortality, unplanned cardiac surgery, or embolic events) was assessed for noninferiority with a 7.5 percentage-point margin. Bacteremia or endocarditis relapse served as a key secondary outcome.
This trial is notable on several levels. Infective endocarditis carries 20–30% in-hospital mortality and the prolonged antibiotic courses have long been associated with catheter-related complications, nephrotoxicity, and Clostridioides difficile infection. If response-guided de-escalation holds up on safety — and the noninferiority framing suggests the investigators anticipated a close result — the clinical practice implications are substantial. The pathogen-stratified design is appropriately rigorous, since S. aureus endocarditis carries a far more aggressive course than streptococcal disease. Key limitations include the open-label design, which introduces potential bias in clinical decision-making, and the restriction to stabilized patients, meaning the sickest cases are excluded by design. This is a potentially paradigm-shifting trial for infectious disease practice, though replication and subgroup analysis by pathogen will be essential before guideline bodies act.